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Objective: To investigate the relationship between serum trough infliximab levels and clinical response to
infliximab treatment in patients with rheumatoid arthritis (RA).
Methods: Disease activity and serum trough infliximab levels before and 2, 6, and 14 weeks after
initiation of infliximab treatment at a dose of 3 mg/kg in a cohort of 105 patients with RA were assessed.
Serum trough infliximab levels in responders and non-responders were compared. Additionally, the
clinical responses of patients with high, intermediate, and low serum trough infliximab levels at 14 weeks
were compared.
Results: After 14 weeks of treatment non-responders had lower serum trough levels of infliximab than
responders (median (interquartile range) 0.5 (0.2–2.2) v 3.6 (1.4–8.2) mg/l; p,0.01)). Patients with low
serum trough infliximab levels at 14 weeks had significantly less improvement in the 28 joint count Disease
Activity Score (DAS28) score than patients with intermediate or high serum trough infliximab levels at
14 weeks. Pretreatment C reactive protein (CRP) levels correlated negatively with serum trough infliximab
levels at 14 weeks after the start of treatment (Spearman rank correlation rs =20.43, p,0.001).
Conclusion: Serum trough levels of infliximab correlate with the clinical response to treatment with
infliximab and pretreatment CRP levels. This study indicates that patients with high pretreatment CRP levels
might benefit from higher dosages of infliximab or shorter dosing intervals.
T
he efficacy of infliximab as a treatment for patients with
active rheumatoid arthritis (RA) has been demonstrated
in randomised controlled trials.1 2 Currently many patients
withactiveRAdespitemethotrexate (MTX) treatment receive a
standardregimenofinfliximabthatconsistsofa3 mg/kginfusion
at 0, 2, and 6 weeks and every 8 weeks thereafter.3 4 However,
despite treatment with infliximab, many patients have
persistent disease activity and some patients do not even
reach response criteria. It might be suggested that in such
patients tumour necrosis factor (TNF) is not completely
neutralised owing to insufficient dosing with infliximab.
The optimal dosing regimen for infliximab is still
unknown. A comparison of response rates across infliximab
treatment groups in the ATTRACT study indicated a dose-
response relationship. Moreover, post hoc analysis of data
from the ATTRACT study provided evidence for a significant
relationship between the extent of clinical improvement and
trough serum concentrations of infliximab.5 Two recent
studies showed that intensification of treatment in non-
responders may lead to a significant decrease in the mean
Disease Activity Score (DAS).6 7 A better understanding of the
relationship between disease activity and serum infliximab
levels may lead to more effective use of this treatment.
Therefore, we developed an assay for the detection of
infliximab in sera and used this to analyse the relationship
between clinical improvement and serum trough infliximab
levels in patients with RA after 14 weeks of treatment with
the standard regimen of 3 mg/kg.
PATIENTS AND METHODS
Patients
One hundred and five consecutive patients with RA receiving
infliximab treatment were included in this open, prospective,
observational study. Patients were enrolled at the depart-
ments of rheumatology of the Slotervaart Hospital and the
VU Medical Centre in Amsterdam from April 2000 to January
2002. Patients were included according to the consensus
statement on the initiation and continuation of TNF blocking
treatments in RA. All patients fulfilled the American College
of Rheumatology 1987 revised criteria for RA8 and all had
evidence of active disease, as indicated by a Disease Activity
Score in 28 joints (DAS28=0.56!(tender joints 28) +
0.28!(swollen joints 28) + 0.70 ln (ESR) + 0.014 (general
health on a visual analogue scale) of .3.2 despite earlier
MTX treatment at a dose of 25 mg weekly or at the maximum
tolerable dose.4 9
All patients were given intravenous infusions of 3 mg/kg of
infliximab at weeks 0, 2, 6, and 14. Concomitant stable drug
treatment, including MTX treatment, was continued. Disease
activity was assessed before each infusion (at weeks 0, 2, 6,
and 14) using the DAS28 score. In addition, serum samples
were collected before each infusion for the assessment of
serum infliximab levels and serum C reactive protein (CRP)
concentration.
Measurement of serum infliximab levels
Infliximab levels were determined by enzyme linked immuno-
sorbent assay (ELISA). Briefly, a mouse monoclonal anti-
body directed against TNF (CLB TNF/7) was coated
overnight at room temperature (2 mg/ml in 100 ml well)
on flat bottomed microtitre plates. Recombinant TNF
Abbreviations: CRP, C reactive protein; DAS28, 28 joint Disease
Activity Score; ELISA, enzyme linked immunosorbent assay; ESR,
erythrocyte sedimentation rate; MTX, methotrexate; RA, rheumatoid
arthritis; TNF, tumour necrosis factor
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(0.1 mg/ml in a 100 ml well) in HPE buffer (CLB BIR,
Amsterdam, The Netherlands) was added for 1 hour. After
washing with phosphate buffered saline/0.2% Tween,
patients’ serum samples were added in different dilutions
in high performance ELISA (HPE) buffer and incubated for
2 hours at room temperature. Plates were washed with
phosphate buffered saline/0.2% Tween, then incubated with
horseradish peroxidase conjugated monoclonal anti human
IgG (MH16) in 100 ml HPE buffer for 1 hour at room
temperature. Subsequently, after washing, tetramethylben-
zidine was added. The reaction was stopped with 2 M
H2SO4. Absorption at 450 nm was then determined in a
multiscan (Multiskan; Titertek, Elfab Oy, Finland). Results
were related to a titration curve of infliximab in each plate.
The lowest level of detection was 0.2 mg/l. Figure 1 shows
a dose-response curve. The ELISA thus captures infliximab
through its ability to bind to TNFa. It does not bind
immune complexes consisting of infliximab and TNF or
infliximab bound by neutralising antibodies.
Serum CRP levels were assessed by immunonephelometry
and used as an indirect marker for TNF production.
Statistical analysis
Patients were classified as responders/non-responders at
14 weeks according to the EULAR response criteria. Non-
response was defined as a DAS28 decrease after 14 weeks of
(0.6, or a decrease .0.6 and (1.2 with an attained DAS of
.5.1.
The relationship between serum infliximab levels and
clinical response was further analysed by categorising
patients into tertiles according to their infliximab level at
14 weeks. The relationship of pretreatment CRP levels and
clinical response was analysed by categorising patients into
tertiles according to their pretreatment CRP level.
Different groups were compared by the Mann-Whitney test
or a two-sided Kruskal-Wallis non-parametric test. The
Spearman rank test was used for correlations between
variables. The threshold for significance was set at p,0.05.
RESULTS
Baseline characteristics of patients
The majority of patients who entered the study were women
(82%), with a mean (SD) age of 56 (13) years, and a mean
(SD) disease duration of 12 (9) years. Seventy per cent of the
patients had tested positive for rheumatoid factor. The mean
number of disease modifying antirheumatic drugs used
before infliximab treatment was 3.7. Eighty six patients used
concomitant methotrexate with a mean dosage of 14 mg
every week. At study entry patients had active disease despite
MTX treatment, as indicated by a mean (SD) DAS28 score of
6.1 (1.3). (Mean (SD) erythrocyte sedimentation rate (ESR)
40 (25), mean (SD) general health 65 (20), mean (SD)
swollen joint count 13 (6), mean (SD) tender joint count 13
(8).)
Clinical response
After 14 weeks of treatment the mean DAS28 score improved
from 6.1 to 4.3. Seventy seven (73%) patients fulfilled the
EULAR response criteria.
Serum infliximab levels
After 2 weeks the median (interquartile range) serum trough
infliximab level was 22.3 (15.3–29.4) mg/l, after a 4 week
interval 14.6 (7.3–22) mg/l, and after 8 weeks 2.8 (0.6–
6.8) mg/l. Serum trough infliximab levels showed consider-
able variation between patients (fig 2). Remarkably, serum
infliximab levels were below the detection limit in the three
serum samples that were collected before all three infusions
that induced an allergic reaction.
After 14 weeks of treatment responders had significantly
(p,0.01) higher median serum trough infliximab concentra-
tions than non-responders (3.6 (1.4–8.2 ) v 0.5 (0.2–2.2) mg/l;
fig 3). With multivariate regression analysis the association
between clinical response and serum trough infliximab
levels at 14 weeks was confirmed. The association between
clinical response and serum trough infliximab remained
significant after correction for potential confounders such
as baseline CRP, baseline DAS28 score, and rheumatoid
factor (data not shown).
To analyse further the relationship between serum
infliximab levels and clinical response, patients were cate-
gorised into three groups according to their infliximab level at
14 weeks. Table 1 shows the results obtained. Patients
categorised as having low serum trough infliximab levels at
14 weeks less often fulfilled the EULAR response criteria
(50% v 90% and 88%) and had significantly less improvement
in the DAS28 score between 1 and 14 weeks (20.9 v 22.0
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Figure 1 Standard curve of infliximab in the ELISA.
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Figure 2 Serum trough infliximab levels in 105 patients treated with
3 mg/kg infliximab. Data are shown as box-whisker plots, representing
the median, 25th and 75th centile, and range.
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Figure 3 Serum trough infliximab levels in patients with RA treated with
infliximab according to clinical response at 14 weeks.
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and 22.4) than patients categorised as having intermediate
or high serum trough infliximab levels. During the shorter
dosing intervals the improvement of all three groups of
patients was similar. However, during the 8 week dosing
interval patients with low serum trough infliximab levels at
14 weeks had an increase in mean disease activity while
patients with intermediate and high serum trough infliximab
levels at 14 weeks showed further improvement in mean
DAS28 score (+0.9 v 20.1 and 20.2).
Pretreatment CRP levels, serum infliximab levels, and
clinical improvement
CRP levels before treatment were used as an indirect marker
for TNF production. Pretreatment CRP levels negatively
correlated with serum infliximab levels at 2 weeks
(rs=20.34, p,0.001), 6 weeks (rs=20.46, p,0.001), and
14 weeks (rs=20.43, p,0.001) (fig 4). To investigate the
relationship between pretreatment CRP levels and clinical
response we categorised patients into three groups according
to their pretreatment CRP level and compared the improve-
ment in DAS28 score. Patients with low (0–10 mg/l)
intermediate (11–40 mg/l), and high (41–120 mg/l) pretreat-
ment CRP levels had a similar improvement in DAS28 score
from 0 to 14 weeks. Moreover the number of EULAR
responders was the same for all three groups. During the
8 week treatment interval, however, the change in the DAS28
score of patients with low pretreatment CRP levels signifi-
cantly differed from that of patients with high pretreatment
CRP values (20.2 (0.6) v 0.6 (1.3), p=0.01). This was seen
for all individual factors which comprise the DAS28 (table 2).
DISCUSSION
We developed an assay for the detection of infliximab in the
serum samples of patients and used this ELISA to investigate
the relationship between serum trough infliximab levels and
clinical response in a large cohort of patients with RA treated
with the standard regimen of 3 mg/kg infliximab. We show
that serum trough levels of infliximab after 14 weeks of
treatment according to this regimen are higher in responders
than in non-responders. In addition, patients with low serum
trough infliximab levels have less improvement in the DAS28
score. Interestingly, we also observed a correlation between
pretreatment CRP and serum infliximab levels and found
that serum infliximab was undetectable before infliximab
infusions that induce an allergic response.
Table 1 Clinical response of patients with low, intermediate, and high serum trough
infliximab levels at 14 weeks
Clinical response
Serum trough infliximab levels at 14 weeks
Low Intermediate High
(0–1.2 mg/l) (1.3–4.7 mg/l) (5.0–25.8 mg/l) Significance
Mean DAS28, t = 0 6.4 6.1 5.8 NS
Mean CRP, t = 0 49 29 17 *
EULAR responders (%) 50 90 88 *
Mean change in DAS28 between
0–2 Weeks 21.3 21.2 21.1 NS
2–6 Weeks 20.4 20.7 21.0 NS
6–14 Weeks 0.9 20.1 20.2 *
0–14 Weeks 20.9 (21.4) 22.0 (21.3) 22.4 (21.4) *
*Indicates statistical significance, NS indicates no statistical significance.
25
20
15
10
5
0
150
C reactive protein before treatment (mg/l)
In
fli
xi
m
ab
 (m
g/
l) 
at
 1
4 
w
ee
ks
0 125100755025
Figure 4 Correlation between serum trough infliximab levels at
14 weeks and CRP values before treatment in patients with RA treated
with infliximab.
Table 2 Clinical response of patients with low, intermediate, and high pretreatment CRP
levels
Clinical response
Pretreatment CRP levels
Significance
Low Intermediate High
(0–10 mg/l) (11–40 mg/l) (41–120 mg/l)
Mean DAS28, t = 0 5.3 6.2 6.8 NS
Mean CRP, t = 0 4 23 68 *
EULAR responders (%) 74 74 71 NS
Mean change in DAS28
0–14 Weeks 21.6 22.0 21.6 NS
0–2 Weeks 20.9 21.3 21.5 NS
2–6 Weeks 20.5 20.9 20.6 NS
6–14 Weeks 20.2 0.2 0.6 *
Mean change in ESR (mm/1st h) 6–14 weeks 21 4 8 *
Mean change in GH (mm) 6–14 weeks 25 5 15 *
Mean change in SJC 6–14 weeks 0 0 3 *
Mean change in TJC 6–14 weeks 21 0 3 *
*Indicates statistical significance, NS indicates no statistical significance.
GH, general health; SJC, swollen joint count; TJC, tender joint count.
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Based on the results of the ATTRACT study most patients
with RA are treated with 3 mg/kg of infliximab every
8 weeks. In clinical practice many patients treated with
infliximab do not reach clinical remission. Many of these
patients are treated with higher dosages of infliximab. Of
interest, the ATTRACT study shows a tendency for the lower
doses to be less effective than the higher doses. A post hoc
analysis of this study suggested a relationship between
clinical response and serum infliximab levels.5 Two recent
studies showed an effect of dose escalation in patients with
insufficient response. This effect was, however, only limited
and might be explained by regression to the mean. Our study
confirms the relationship between clinical response and
serum through infliximab levels as shown by St Clair et al5
and extends these observations. As infliximab is expensive it
might be efficient to adjust the infliximab dosing schedule
after measurement of the serum infliximab concentration.
We used pretreatment CRP levels as an indirect marker of
TNF production. We observed a correlation between pre-
treatment CRP levels, serum trough infliximab levels, and
clinical response. Higher levels of TNF production in patients
with high CRP levels might explain this relationship.
Furthermore, it is possible that infliximab-TNF complexes
are cleared from the circulation at a faster rate than unbound
infliximab. The clinical implication of this finding is that
patients with high pretreatment CRP levels might benefit
more from higher dosages of infliximab than patients with
low pretreatment CRP levels.
The chimerical antibody infliximab may induce infusion
related allergic reactions, which are associated with the
formation of anti-infliximab antibodies.2 10 In all three
patients with a clinically overt infusion reaction serum
concentrations of infliximab before the infusion that elicited
the reaction were below the detection limit of our assay. This
could be due to the binding of infliximab by immune
complexes or by anti-infliximab antibodies.
Despite treatment with infliximab infusions many patients
with RA still have persistent disease activity. The response to
infliximab treatment is related to serum infliximab levels and
shows a large variation between patients. Further investiga-
tion into the mechanisms that determine serum concentra-
tions of infliximab may help to optimise this treatment.
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